Study of Inhaled Nitric Oxide Treatment in Adults Aged 40 to 75 with Moderate-to-Severe COPD

What this Trial Is About

Researchers are evaluating inhaled nitric oxide to understand its effects on exercise tolerance and safety in people with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. This study aims to help develop better treatment options for managing COPD symptoms and improving patient outcomes. The trial is sponsored by Novlead Inc. and does not involve a specific drug phase classification. Participants will be randomly assigned to receive inhaled nitric oxide at either 10 parts per million ppm or 40 ppm. Each participant will inhale the gas for at least 2 hours each day over a period of 7 consecutive days. The nitric oxide is delivered using a specialized device that controls the concentration of gas inhaled through the breathing apparatus. During the study, participants will be closely monitored with various tests and assessments. These include measuring changes in oxygen uptake, breathing efficiency, perceived exertion, lung function, walking distance, and COPD symptom scores, all recorded at the beginning and end of the 7-day treatment period. Safety and treatment effects will be assessed throughout, with the total participation lasting just over one week.

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease